CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 130 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q4 2020. The put-call ratio across all filers is 0.95 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $625,092 | -30.7% | 18,423 | -26.6% | 0.00% | -33.3% |
| Q1 2023 | $902,522 | +7.8% | 25,084 | -15.8% | 0.00% | 0.0% |
| Q3 2022 | $837,000 | -88.7% | 29,780 | -89.1% | 0.00% | -87.5% |
| Q2 2022 | $7,377,000 | -5.4% | 273,620 | +19.5% | 0.02% | +4.3% |
| Q1 2022 | $7,798,000 | +4.2% | 228,948 | +18.2% | 0.02% | +43.8% |
| Q4 2021 | $7,482,000 | +117.0% | 193,641 | -1.6% | 0.02% | +60.0% |
| Q4 2020 | $3,448,000 | -40.4% | 196,792 | -49.5% | 0.01% | -52.4% |
| Q3 2020 | $5,783,000 | +239.4% | 389,942 | +197.5% | 0.02% | +162.5% |
| Q2 2020 | $1,704,000 | +1752.2% | 131,094 | +282.1% | 0.01% | – |
| Q2 2019 | $92,000 | – | 34,308 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 3,200,000 | $88,064,000 | 14.40% |
| Octagon Capital Advisors LP | 759,898 | $20,912,393 | 3.21% |
| TSP Capital Management Group, LLC | 251,695 | $6,926,645 | 2.67% |
| 5AM Venture Management, LLC | 310,270 | $8,538,630 | 2.46% |
| COMMODORE CAPITAL LP | 706,665 | $19,447,421 | 2.27% |
| ACUTA CAPITAL PARTNERS, LLC | 122,341 | $3,366,824 | 2.26% |
| Redmile Group, LLC | 1,635,938 | $45,021,014 | 2.14% |
| RTW INVESTMENTS, LP | 3,463,201 | $95,307,292 | 2.01% |
| Eversept Partners, LP | 588,143 | $16,185,695 | 1.37% |
| Affinity Asset Advisors, LLC | 150,000 | $4,128,000 | 1.16% |